Deploying Kinase Inhibitors to Study Pediatric Gliomas
Benjamin T Himes1, Liang Zhang1, David J Daniels2
1Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA.
Abstract:
Pediatric midline gliomas are a uniformly fatal disease for which there is no cure. The location of these tumors makes surgical resection impossible, and so novel therapies are urgently needed to improve outcomes. The biology of these tumors is increasingly understood, with the histone H3K27M mutation playing a critical role in the pathogenesis of these tumors. Efforts to inhibit the growth of these tumors have also focused on inhibiting the Aurora kinase and Janus-associated kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in order to disrupt tumor proliferation. A number of small molecule inhibitors of these kinases have shown promise in early studies. Screening and preclinical assessment of such inhibitors requires a functional assay to assess the degree of kinase inhibition. We detail here a luciferase-based reporter assay for STAT3 transcriptional activity that we have employed frequently in order to assess the efficacy of kinase inhibitors in pediatric gliomas. The assay we describe is specific to STAT3, but the overall methodology is generalizable to other downstream targets of the kinase of interest.
Insights
Pediatric midline gliomas lack cures. This study details a luciferase reporter assay to evaluate kinase inhibitors targeting STAT3, aiding the development of novel therapies for these fatal brain tumors.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Pediatric midline gliomas are aggressive brain tumors with no effective treatments.
- The histone H3K27M mutation is a key driver in the pathogenesis of these gliomas.
- Targeting Aurora kinase and the Janus-associated kinase (JAK)/signal transducer and activator of transcription (STAT) pathway shows therapeutic promise.
Purpose of the Study:
- To describe a functional assay for assessing kinase inhibitor efficacy in pediatric gliomas.
- To validate a luciferase reporter assay for STAT3 transcriptional activity.
Main Methods:
- Development and application of a luciferase-based reporter assay.
- Assay specifically measures STAT3 transcriptional activity.
- Used to screen and assess preclinical efficacy of kinase inhibitors.
Main Results:
- The assay provides a functional readout of kinase inhibition.
- Demonstrated utility in evaluating inhibitors targeting pediatric glioma pathways.
- Methodology is adaptable for other kinase targets.
Conclusions:
- A validated luciferase reporter assay for STAT3 activity is crucial for preclinical assessment of kinase inhibitors.
- This assay facilitates the development of novel therapeutic strategies for pediatric gliomas.
- The described methodology can be generalized to assess other kinase-driven pathways.
Related Concept Videos
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism